The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway
Open accessAbstract
TEA domain (TEAD) transcription factors bind to the coactivators YAP and TAZ and regulate the transcriptional output of the Hippo pathway, playing critical roles in organ size control and tumorigenesis. Protein S-palmitoylation attaches a fatty acid, palmitate, to cysteine residues and regulates protein trafficking, membrane localization and signaling activities. Using activity-based chemical probes, we discovered that human TEADs possess intrinsic palmitoylating enzyme-like activities and undergo autopalmitoylation at evolutionarily conserved cysteine residues under physiological conditions. We determined the crystal structures of lipid-bound TEADs and found that the lipid chain of palmitate inserts into a conserved deep hydrophobic pocket. Strikingly, palmitoylation did not alter TEAD's localization, but it was required for TEAD's binding to YAP and TAZ and was dispensable for its binding to the Vgll4 tumor suppressor. Moreover, palmitoylation-deficient TEAD mutants impaired TAZ-mediated muscle differentiation in vitro and tissue overgrowth mediated by the Drosophila YAP homolog Yorkie in vivo. Our study directly links autopalmitoylation to the transcriptional regulation of the Hippo pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“YAP/TAZ primarily pairs with the TEAD family of TFs to induce gene expression signatures that play an important role in cancer development, progression, and metastasis.435,436”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [436]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Self-citationThe Hippo Signaling Pathway in Development and Cancer
Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.011 · Cited by 2,317
Self-citationThe Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3458 · Cited by 1,867
Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
Self-citationThe two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R. L., & Halder, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 920
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O. D., Young, M. A., Scheffzek, K., Veach, D. R., Bornmann, W. G., Clarkson, B., Superti‐Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 880
Metabolic control of YAP and TAZ by the mevalonate pathway
Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2936 · Cited by 776
Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling
Færgeman, N. J., & Knudsen, J. (1997) · Biochemical Journal · doi:10.1042/bj3230001 · Cited by 681
Cited by
Sorted by citations
The Hippo Signaling Pathway in Development and Disease
Zheng, Y., & Pan, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.003 · Cited by 867
Self-citationTargeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 823
The role of lipids in cancer progression and metastasis
Martín‐Pérez, M., Urdiroz-Urricelqui, U., Bigas, C., & Benitah, S. A. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.023 · Cited by 600
Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies
Jiang, H., Zhang, X., Chen, X., Aramsangtienchai, P., Tong, Z., & Lin, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00750 · Cited by 518
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
Interplay between YAP/TAZ and Metabolism
Koo, J. H., & Guan, K. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.010 · Cited by 478
Protein palmitoylation and cancer
Ko, P., & Dixon, S. J. (2018) · EMBO Reports · doi:10.15252/embr.201846666 · Cited by 442
Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.04.001 · Cited by 433
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Regulation of the Hippo Pathway Transcription Factor TEAD
Lin, K. C., Park, H. W., & Guan, K. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.09.003 · Cited by 345
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 355
Fatty acylation of proteins: The long and the short of it
Resh, M. D. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.05.002 · Cited by 286
Chen, B., Sun, Y., Niu, J., Jarugumilli, G. K., & Wu, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.003 · Cited by 284
Self-citationFluorescent probes for the detection of disease-associated biomarkers
Dou, W., Han, H., Sedgwick, A. C., Zhu, G.-B., Zang, Y., Yang, X., Yoon, J., James, T. D., Li, J. X., & He, X. (2022) · 中国科学通报：英文版 · doi:10.1016/j.scib.2022.01.014 · Cited by 267
Tang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J., Yu, F.-X., Guan, K.-L., & Post, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0717 · Cited by 245
Regulation of TEAD Transcription Factors in Cancer Biology
Huh, H., Kim, D., Jeong, H.-S., & Park, H. (2019) · Cells · doi:10.3390/cells8060600 · Cited by 259
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Piccolo, S., Panciera, T., Contessotto, P., & Cordenonsi, M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00473-z · Cited by 264
A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy
Pobbati, A. V., & Hong, W. (2020) · Theranostics · doi:10.7150/thno.40889 · Cited by 230
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Li, Q., Sun, Y., Jarugumilli, G. K., Liu, S., Dang, K., Cotton, J. L., Xiol, J., Chan, P. Y., DeRan, M., Ma, L., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.03.002 · Cited by 180
Self-citationThe role of YAP/TAZ activity in cancer metabolic reprogramming
Zhang, X., Zhao, H., Li, Y., Xia, D., Yang, L., Ma, Y., & Li, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0882-1 · Cited by 212
Bum‐Erdene, K., Zhou, D., González-Gutiérrez, G., Ghozayel, M. K., Si, Y., Xu, D. D., Shannon, H. E., Bailey, B. J., Corson, T. W., Pollok, K. E., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.11.010 · Cited by 208
The Role of Hippo Pathway in Cancer Stem Cell Biology.
Park, J. H., Shin, J. E., & Park, H. W. (2018) · PubMed Central · doi:10.14348/molcells.2018.2242 · Cited by 197
Integration of Hippo-YAP Signaling with Metabolism
Ibar, C., & Irvine, K. D. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.025 · Cited by 190
Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1
Xu, H., Zhao, H., Ding, C., Jiang, D., Zhao, Z., Li, Y., Ding, X., Gao, J., Zhou, H., Luo, C., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01231-4 · Cited by 194
Metabolites Regulate Cell Signaling and Growth via Covalent Modification of Proteins
Figlia, G., Willnow, P., & Teleman, A. A. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.036 · Cited by 185
Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors
Holden, J. K., & Cunningham, C. N. (2018) · Cancers · doi:10.3390/cancers10030081 · Cited by 181
Holden, J. K., Crawford, J. J., Noland, C. L., Schmidt, S., Zbieg, J. R., Lacap, J. A., Zang, R., Miller, G. M., Zhang, Y., Beroza, P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107809 · Cited by 172
Control of stem cell renewal and fate by YAP and TAZ
Driskill, J. H., & Pan, D. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00644-5 · Cited by 173
Self-citationTherapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
Dynamic Protein Acylation: New Substrates, Mechanisms, and Drug Targets
Lanyon‐Hogg, T., Faronato, M., Serwa, R. A., & Tate, E. W. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.04.004 · Cited by 149
Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells
Sun, Y., Hu, L., Tao, Z., Jarugumilli, G. K., Erb, H., Singh, A., Li, Q., Cotton, J. L., Greninger, P., Egan, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34559-0 · Cited by 145
Self-citationKaneda, A., Seike, T., Danjo, T., Nakajima, T., Otsubo, N., Yamaguchi, D., Tsuji, Y., Hamaguchi, K., Yasunaga, M., Nishiya, Y., et al. (2020) · PubMed Central · Cited by 139
ABHD10 is an S-depalmitoylase affecting redox homeostasis through peroxiredoxin-5
Cao, Y., Qiu, T., Kathayat, R. S., Azizi, S., Thorne, A. K., Ahn, D. J., Fukata, Y., Fukata, M., Rice, P. A., & Dickinson, B. C. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0399-y · Cited by 137
A Not-So-Ancient Grease History: Click Chemistry and Protein Lipid Modifications
Suazo, K. F., Park, K., & Distefano, M. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01108 · Cited by 120
TEAD family transcription factors in development and disease
Currey, L., Thor, S., & Piper, M. (2021) · Development · doi:10.1242/dev.196675 · Cited by 120
ZDHHC7-mediated S-palmitoylation of Scribble regulates cell polarity
Chen, B., Zheng, B., DeRan, M., Jarugumilli, G. K., Fu, J., Brooks, Y. S., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2119 · Cited by 119
Self-citationYap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth
Cox, A. G., Tsomides, A., Yimlamai, D., Hwang, K. L., Miesfeld, J. B., Galli, G. G., Fowl, B. H., Fort, M. W., Kimberly, Y., Sullivan, M. R., et al. (2018) · The EMBO Journal · doi:10.15252/embj.2018100294 · Cited by 116
Protein Palmitoylation and Its Role in Bacterial and Viral Infections
Sobocińska, J., Roszczenko, P., Ciesielska, A., & Kwiatkowska, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.02003 · Cited by 122
Kaan, H. Y. K., Chan, S. W., Tan, S. K. J., Guo, F., Lim, C. J., Hong, W., & Song, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-02219-9 · Cited by 118
Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes
Kathayat, R. S., Cao, Y., Elvira, P. D., Sandoz, P. A., Zaballa, M.-E., Springer, M. Z., Drake, L. E., Macleod, K. F., van der Goot, F. G., & Dickinson, B. C. (2018) · Nature Communications · doi:10.1038/s41467-017-02655-1 · Cited by 109
The molecular era of protein S-acylation: spotlight on structure, mechanisms, and dynamics
Zaballa, M.-E., & van der Goot, F. G. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1488804 · Cited by 109
Lipid-induced S-palmitoylation as a Vital Regulator of Cell Signaling and Disease Development
Qu, M., Zhou, X., Wang, X., & Li, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64046 · Cited by 112
GPCR-Hippo Signaling in Cancer
Luo, J., & Yu, F. (2019) · Cells · doi:10.3390/cells8050426 · Cited by 112
Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
Li, Q., & Kang, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155262 · Cited by 103
Targeting Transcriptional Enhanced Associate Domains (TEADs)
Gibault, F., Sturbaut, M., Bailly, F., Melnyk, P., & Cotelle, P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00879 · Cited by 102
Mediated nuclear import and export of TAZ and the underlying molecular requirements
Kofler, M., Speight, P., Little, D., Ciano‐Oliveira, C. D., Szászi, K., & Kapùs, A. (2018) · Nature Communications · doi:10.1038/s41467-018-07450-0 · Cited by 105
The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin
Rognoni, E., & Walko, G. (2019) · Cells · doi:10.3390/cells8050411 · Cited by 106
A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations
Yamaguchi, H., & Taouk, G. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00928 · Cited by 106
Liu, Y., Zhang, H., Liu, Y., Zhang, S., Su, P., Wang, L., Li, Y., Liang, Y., Wang, X., Zhao, W., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2182482 · Cited by 100
Lu, W., Wang, J., Li, Y., Tao, H., Xiong, H., Lian, F., Gao, J., Ma, H., Lu, T., Zhang, D., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111767 · Cited by 94
Talukdar, P. D., & Chatterji, U. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01651-w · Cited by 103
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer
Baroja, I., Kyriakidis, N. C., Halder, G. A., & Moya, I. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46531-1 · Cited by 96
A Decade of Click Chemistry in Protein Palmitoylation: Impact on Discovery and New Biology
Gao, X., & Hannoush, R. N. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.12.002 · Cited by 91
Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity
Kim, N., & Gumbiner, B. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819400116 · Cited by 93
Jeong, D., Park, J., Kim, K.-S., Kim, J., Huh, J., Seo, J., Kim, Y., Cho, J., Lee, K., Fukuda, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42170-0 · Cited by 91
Osman, I., He, X., Liu, J., Dong, K., Wen, T., Zhang, F., Yu, L., Hu, G., Xin, H., Zhang, W., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314187 · Cited by 89
Mokhtari, R. B., Ashayeri, N., Baghaie, L., Sambi, M., Satari, K., Baluch, N., Bosykh, D. A., Szewczuk, M. R., & Chakraborty, S. (2023) · Cancers · doi:10.3390/cancers15133468 · Cited by 92
Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review
Crawford, J. J., Bronner, S. M., & Zbieg, J. R. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1549226 · Cited by 85
Structure and function of DHHC protein S-acyltransferases
Gottlieb, C. D., & Linder, M. E. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160304 · Cited by 85
Structure and Mechanism of DHHC Protein Acyltransferases
Stix, R., Lee, C., Faraldo‐Gómez, J. D., & Banerjee, A. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.05.023 · Cited by 84
Aflatoxin Biosynthesis, Genetic Regulation, Toxicity, and Control Strategies: A Review
Khan, R., Ghazali, F. M., Mahyudin, N. A., & Samsudin, N. I. P. (2021) · Journal of Fungi · doi:10.3390/jof7080606 · Cited by 83
Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
Pellerin, L., Carrié, L., Dufau, C., Nieto, L., Ségui, B., Levade, T., Riond, J., & Andrieu‐Abadie, N. (2020) · Cancers · doi:10.3390/cancers12113147 · Cited by 91
New insights into the ambivalent role of YAP/TAZ in human cancers
Luo, J., Deng, L., Zou, H., Guo, Y., Tong, T., Huang, M., Ling, G., & Li, P. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02704-2 · Cited by 89
A fluorescent probe for cysteine depalmitoylation reveals dynamic APT signaling
Kathayat, R. S., Elvira, P. D., & Dickinson, B. C. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2262 · Cited by 81
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
Yap, T. A., Kwiatkowski, D. J., Dagogo‐Jack, I., Offin, M. D., Zauderer, M. G., Kratzke, R. A., Desai, J., Body, A. L., Millward, M., Tolcher, A. W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04029-3 · Cited by 91
Regulation of the Hippo pathway in cancer biology
Moon, S., Park, S. Y., & Park, H. W. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2804-1 · Cited by 77
Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106
Heinrich, T., Peterson, C., Schneider, R., Garg, S., Schwarz, D. F., Gunera, J., Seshire, A., Kötzner, L., Schlesiger, S., Müsil, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00403 · Cited by 76
Diverse Roles of Protein Palmitoylation in Cancer Progression, Immunity, Stemness, and Beyond
Li, M., Zhang, L., & Chen, C.-W. D. (2023) · Cells · doi:10.3390/cells12182209 · Cited by 76
Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness
Espinosa-Sánchez, A., Suárez-Martínez, E., Sánchez-Díaz, L., & Carnero, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01533 · Cited by 77
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine
Barry, E., Simov, V., Valtingojer, I., & Venier, O. (2021) · Cells · doi:10.3390/cells10102715 · Cited by 73
Effect of the acylation of TEAD4 on its interaction with co‐activators YAP and TAZ
Mesrouze, Y., Meyerhofer, M., Bokhovchuk, F. M., Fontana, P., Zimmermann, C., Martin, T., Delaunay, C., Izaac, A., Kallen, J. A., Schmelzle, T., et al. (2017) · Protein Science · doi:10.1002/pro.3312 · Cited by 71
DNA-binding mechanism of the Hippo pathway transcription factor TEAD4
Shi, Z., He, F., Chen, M., Hua, L., Wang, W., Jiao, S., & Zhou, Z. (2017) · Oncogene · doi:10.1038/onc.2017.24 · Cited by 69
Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
Fan, M., Lu, W., Che, J., Kwiatkowski, N. P., Gao, Y., Seo, H.-S., Ficarro, S. B., Gokhale, P. C., Liu, Y., Geffken, E. A., et al. (2022) · eLife · doi:10.7554/elife.78810 · Cited by 68
YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
Coggins, G. E., Farrel, A., Rathi, K. S., Hayes, C. M., Scolaro, L., Rokita, J. L., & Maris, J. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1415 · Cited by 66
Karataş, H., Akbarzadeh, M., Adihou, H., Hahne, G., Pobbati, A. V., Ng, E. Y., Guéret, S. M., Sievers, S., Pahl, A., Metz, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01275 · Cited by 66
The oncogenic roles and clinical implications of YAP/TAZ in breast cancer
Luo, J., Zou, H., Guo, Y., Tong, T., Chen, Y., Xiao, Y., Pan, Y., & Li, P. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02182-5 · Cited by 72
Targeting the Hippo pathway in cancer
Harvey, K. F., & Tang, T. T.-L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01234-0 · Cited by 68
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Tate, E. W., Soday, L., de la Lastra, A. L., Wang, M., & Lin, H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00666-x · Cited by 63
Mesrouze, Y., Bokhovchuk, F. M., Meyerhofer, M., Fontana, P., Zimmermann, C., Martin, T., Delaunay, C., Erdmann, D., Schmelzle, T., & Chêne, P. (2017) · eLife · doi:10.7554/elife.25068 · Cited by 60
Yu, Y., Su, X., Qin, Q., Hou, Y., Zhang, X., Zhang, H., Jia, M., & Chen, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105009 · Cited by 61
Vaidyanathan, S., Salmi, T. M., Sathiqu, R. M., McConville, M. J., Cox, A. G., & Brown, K. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.02.004 · Cited by 58
Structural and Functional Overview of TEAD4 in Cancer Biology
Chen, M., Huang, B., Zhu, L., Chen, K., Liu, M., & Zhong, C. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266649 · Cited by 54
Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors
Lu, W., Fan, M., Ji, W., Tse, J., You, I., Ficarro, S. B., Tavares, I., Che, J., Kim, A. Y., Zhu, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01548 · Cited by 52
Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex
Pobbati, A. V., & Rubin, B. P. (2020) · Molecules · doi:10.3390/molecules25246001 · Cited by 55
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)
Zagiel, B., Melnyk, P., & Cotelle, P. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2096436 · Cited by 50
Biomolecular condensates: hubs of Hippo-YAP/TAZ signaling in cancer
Kiang, K. M. Y., Ahad, L., Zhong, X., & Lu, Q. R. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.04.009 · Cited by 56
Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3
Lu, T., Li, Y., Lu, W., Spitters, T., Fang, X., Wang, J., Cai, S., Gao, J., Zhou, Y., Duan, Z., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.015 · Cited by 50
Identification of Quinolinols as Activators of TEAD-Dependent Transcription
Pobbati, A. V., Mejuch, T., Chakraborty, S., Karataş, H., Bharath, S. R., Guéret, S. M., Goy, P.-A. V., Hahne, G., Pahl, A., Sievers, S., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00786 · Cited by 51
Targeting Hippo signaling in cancer: novel perspectives and therapeutic potential
Lv, L., & Zhou, X. (2023) · MedComm · doi:10.1002/mco2.375 · Cited by 46
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Kumar, R., & Hong, W. (2024) · Cells · doi:10.3390/cells13070564 · Cited by 47
Wu, L., Yang, Y., Li, B., Huang, W., Wang, X., Liu, X., Meng, Z., & Xia, J. (2019) · Marine Biotechnology · doi:10.1007/s10126-019-09916-8 · Cited by 47
Gadalla, M. R., & Veit, M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696306 · Cited by 44
Hu, L., Sun, Y., Liu, S., Erb, H., Singh, A., Mao, J., Luo, X., & Wu, X. (2022) · eLife · doi:10.7554/elife.80210 · Cited by 49
Self-citationThe Hippo pathway: Organ size control and beyond
Guo, P., Wan, S., & Guan, K. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100031 · Cited by 51
Repurposing of Drugs Targeting YAP-TEAD Functions
Elisi, G. M., Santucci, M., D’Arca, D., Lauriola, A., Marverti, G., Losi, L., Scalvini, L., Bolognesi, M. L., Mor, M., & Costi, M. P. (2018) · Cancers · doi:10.3390/cancers10090329 · Cited by 47
Kim, H., & Nam, J. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01551-9 · Cited by 55
Metadata
- Authors
- Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X.
- Affiliations
- Harvard University (US)
- Jilin University (CN)
- Howard Hughes Medical Institute (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Luo, Xuelian
- Wu, Xu
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2016-02-22
- Volume
- 12
- Issue
- 4
- Pages
- 282-289
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC4798901
- OpenAlex
- W2274646531
- Cited by
- 313
- References
- 49
- Citations by year
- 2026: 40 · 2025: 38 · 2024: 54 · 2023: 37 · 2022: 39 · 2021: 21 · 2020: 26 · 2019: 19 · 2018: 21 · 2017: 13 · 2016: 4
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Defense (DE-AC02-06CH11357, R01CA181537, W81XWH, R01DK107651, W81XWH-13)
- Howard Hughes Medical Institute
- U.S. Department of Energy (DE‐ AC02‐06CH11357, AC02‐06CH11357, 06CH11357, DE-AC02-)
- Melanoma Research Alliance (R01CA181537, R01DK107651)
- University of Texas Southwestern Medical Center
- National Institutes of Health (DE-AC02–06CH11357, W81XWH)
- National Eye Institute (R01EY015708)
- National Cancer Institute (R01CA181537, DE-AC02-06CH11357)
- National Institute of General Medical Sciences (DE-AC02-06CH11357, R01GM107415)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK107651)
- Argonne National Laboratory (DE- AC02-06-CH11357, DE-AC02, AC02–06CH11357, 06CH11357)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- TEAD transcription factors, S-palmitoylation, Hippo signaling pathway, YAP, TAZ, VGLL4, protein lipidation, transcriptional regulation, myogenesis, tissue overgrowth, Yorkie, organ size control
- MeSH terms
- Hippo Signaling Pathway, YAP-Signaling Proteins, TEA Domain Transcription Factors, Amino Acid Sequence, Animals, Cell Differentiation, Cell Line, Cysteine, DNA-Binding Proteins, Fatty Acids, Unsaturated, Humans, Models, Molecular, Molecular Sequence Data, Nuclear Proteins, Palmitates, Protein Binding, Transcription Factors, Signal Transduction, Trans-Activators, Sequence Alignment, Conserved Sequence, Protein Serine-Threonine Kinases, Muscle Fibers, Skeletal, Protein Transport, Drosophila Proteins, Lipoylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
